Возможность применения липосомального альфа-2в интерферона для профилактики гриппа и других острых респираторных инфекций

TL;DRAbstract

WITHIN RECENT YEARS, A SPECIAL ATTENTION HAS BEEN PAID TO THE NONSPECIFIC PREVENTION OF THE ACUTE RESPIRATORY DISEASE RELATED TO THE INCREASE OF THE ACTIVITY OF THE NATURAL MECHANISMS FOR ANTIVIRAL PROTECTION. THE APPLICATION OF THE LIPOSOMAL FORMS OF THE DIFFERENT MEDICATIONS CONTRIBUTES TO THE DIRECTED TRANSPORTATION OF THE BIODEGRADED PROTEIN SUBSTANCES. A SPECIAL INTEREST IS AROUSED BY THE OPPORTUNITY TO ORALLY APPLY PROTEIN MEDICATIONS, AS THEIR INJECTION FORMS QUICKLY DEGRADE IN THE STOMACH. NEW RUSSIAN LIPOSOMAL RECOMBINANT ALPHA-2B INTERFERON HAS ANTIVIRAL, IMMUNOMODULAT-ING AND INTERFERONOGENIC ACTIVITY. THE WORK DEMONSTRATES EXPERIENCE OF THE ORAL APPLICATION FORM OF THE LIPOSOMAL MEDICATION OF RECOMBINANT ALPHA-2B INTERFERON REAFERON-ES-LIPINT FOR THE EXTRA PREVENTION OF FLU AND OTHER ACUTE RESPIRATORY INFECTIONS AMONG CHILDREN. THE APPLICATION OF THIS MEDICATION TO PREVENT FLU AND ACUTE RESPIRATORY INFECTIONS IN THE DOSE OF 250,000 МЕ TWICE A WEEK FOR THE 4 WEEKS' PERIOD PR

Chat with Paper

AI Agents for this Paper